Ziad Khoury, MD
Nephrology · Chevy Chase, MDNPI 1285075218
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,358 of the $7,069 with a category attached, or 75.8%. It is spread thinly across 24 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$717
- Novartis$698
- Travere Therapeutics, Inc.$653
- Vifor Pharma, Inc.$646
- AstraZeneca$642
- Amgen$604
- plus $3K from 18 others
What the payments were for
- Consulting fees$83312%
- Speaking & faculty fees$5808%
- Food & beverage$5,35876%
- Education$2984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 32 | $717 |
| Novartis | 29 | $698 |
| Travere Therapeutics, Inc. | 21 | $653 |
| Vifor Pharma, Inc. | 23 | $646 |
| AstraZeneca(2 entities) | 27 | $642 |
| Amgen(2 entities) | 26 | $604 |
| BD | 2 | $393 |
| Ardelyx, Inc. | 17 | $388 |
| OPKO Pharmaceuticals, LLC | 19 | $367 |
| Fresenius USA Marketing, Inc. | 14 | $271 |
| Lilly USA, LLC | 11 | $263 |
| Akebia Therapeutics Inc | 11 | $229 |
| Novo Nordisk | 7 | $165 |
| Calliditas Therapeutics US Inc. | 6 | $157 |
| Bayer | 7 | $138 |
| Aurinia Pharma U.S., Inc. | 7 | $136 |
| Sentynl Therapeutics, Inc. | 1 | $129 |
| GSK | 6 | $127 |
| Baxter Healthcare | 2 | $102 |
| ZOLL Medical Corporation | 1 | $92 |
| Boehringer Ingelheim | 3 | $72 |
| Scpharmaceuticals Inc. | 1 | $34 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Nxstage Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,069 in reported general payments places this provider in the 90th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 46 | $70,301 |
| VeltassaPatiromer Calcium Sorbitex | 39 | $57,845 |
| FarxigaDapagliflozin Propanediol | 50 | $57,665 |
| JardianceEmpagliflozin | 39 | $54,549 |
| VelphoroSucroferric Oxyhydroxide | 18 | $42,454 |
| AranespDarbepoetin Alfa In Polysorbat | 22 | $23,990 |
| Sevelamer Carbonate | 61 | $19,985 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $13,285 |
| Cinacalcet Hcl | 14 | $9,087 |
| Olmesartan Medoxomil | 139 | $2,770 |
| Candesartan Cilexetil | 26 | $1,945 |
| Valsartan | 41 | $1,664 |
| Potassium Citrate ErPotassium Citrate | 21 | $1,494 |
| Allopurinol | 142 | $1,303 |
| Losartan Potassium | 63 | $873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $642 | $70,95067 claims |
| BayerKerendia | $138 | $70,30146 claims |
| Boehringer IngelheimJardiance | $72 | $54,54939 claims |
| Fresenius USA Marketing, Inc.Velphoro | $271 | $42,45418 claims |
| AmgenAranesp | $604 | $23,99022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 nephrology providers in Maryland.
Other nephrology in Chevy Chase
- Steven BurkaChevy Chase$8K
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Eli RozaHagerstown$79K
- Mohamed AttaBaltimore$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.